ABIVAX___________

NAME OF THE CEOProf Hartmut Ehrlich, M.D.

ADDRESS5 rue de la Baume,

75008 Paris

___________________

EMAILinfo@abivax.com

www.abivax.com

MANAGEMENT TEAMCEO: Prof. Hartmut Ehrlich, M.D.

CFO: Didier Blondel

CMO: Jean-Marc Steens, M.D.

CCO & VP BD: Pierre Courteille

TARGETED

MARKET____________

• HIV: Towards a functional cure for HIV: Targeting RNA splicing

• IBD (Ulcerative Colitis & Crohn’s Disease)

• Immuno-oncology in HCC in combination with checkpoint

inhibitors

LISTED COMPANY

CREATION DATEDecember 2013

MISSIONABIV AX i s a b i o techno l og y com p any ha r nes s i ng t he i m m une s y s tem to d ev e l op a f unc t i ona l cu r e f o r H IV and t r ea tm en ts f o r i n f l am m ato r y d i s eas es and cance r .

TECHNOLOGYABIV AX l ev e r ag es t h r ee t echno l og y p l a t f o r m s f o r d r ug d i s cov e r y :• an antiviral platform• an immune enhancement platform• a polyclonal antibody platform

ALLIANCES/PARTNERSHIPS

Par t n ersh ip s• CNRS / Curie Institute Licenses• Scripps Research Institute

UPCOMING CATALYSTS

MARKET FIGURESRev enues 2017 : 0 €D ate o f IP O : J une 2015T i ck e r : ABV X .P AE x chang e : E u r onex t P a r i sC ur r ency : €M ar k e t cap : 72 m i l l i on € ( as o f M ay 3 , 2018 )P r i ce : 7 .33 € ( as o f M ay 3 , 2018 )52 - w eek s - h i g h : 18 .76 €52 - w eek s - l ow : 7 €Av er ag e d a i l y v o l um e : 52000 p e r d ay i n 2017

KEY FIGURES

COMPANY SUMMARY

BIO Boston 1x1 meeting

Ex-Head of Global R&D, Baxter BioScience

Prof. Hartmut Ehrlich, M.D.Chief Executive Officer

19

ABX464 HIV

ABX464 UC

ABX196 HCC

Q2 2018 Q3 2018 Q4 2018 Q1 2019 key operational milestones

2018 will be a transformative year for ABIVAX

IND1 Filing

Topline data 005-study

FSI2 Phase IIb

Topline data 101-study

IND Filing

FSI Phase IIb

IND Filing

FSI HCC- Phase I/II

Candidate

1: IND = Investigational new drug 2: FSI = First subject in

€ m 2016 2017 Growth (%)Sales 0 0 0%EBIT -18 -14 22%Net Income -14 -11 21%Cash Position 17 23 -26%

ABIVAX___________

NAME OF THE CEOProf Hartmut Ehrlich, M.D.

ADDRESS5 rue de la Baume,

75008 Paris

___________________

EMAILinfo@abivax.com

www.abivax.com

MANAGEMENT TEAMCEO: Prof. Hartmut Ehrlich, M.D.

CFO: Didier Blondel

CMO: Jean-Marc Steens, M.D.

CCO & VP BD: Pierre Courteille

TARGETED

MARKET____________

• HIV: Towards a functional cure for HIV: Targeting RNA splicing

• IBD (Ulcerative Colitis & Crohn’s Disease)

• Immuno-oncology in HCC in combination with checkpoint

inhibitors

LISTED COMPANY

CREATION DATEDecember 2013

ANALYST COVERAGE

COMPANY SUMMARY

BIO Boston 1x1 meeting

Ex-Head of Global R&D, Baxter BioScience

Prof. Hartmut Ehrlich, M.D.Chief Executive Officer

Broker Date Reco. (buy/neutral/hold)

Target Price Potential (%)

NIBCGoetz Partners

RBC

03/201810/201705/2017

BuyBuyBuy

15,10 €19,50 €26,00 €

+106%+166%+255%

Average: - Buy 20,2 € +176%

SHAREHOLDERS

Truffle Capital

60%

Founders2%

Incubator Holding

3%

Public35%

Shareholder structure2 (undiluted)

PIPELINE

17

Preclinical Phase 1 Phase 2 Phase 3

In 3rd Phase 2

In Phase 2 POC

ABX464

ABX464

ABX196

ABX544

Research Lead

generation

Clinical trial in HCC to start Q4 2018

HIV Lasting viral remission

Ulcerative Colitis

Anti-inflammatory

Cancer

Immune enhancer

Ebola

Polyclonal antibodies

Dengue

Antiviral drug Respiratory

Syncytial Virus Antiviral drug

Influenza Antiviral drug

ABIVAX has a mature and growing pipeline

As of December 31st , 2017